Statin‑associated myasthenia gravis: a real-world retrospective and pharmacovigilance study
Expert Opinion on Drug Safety · 2025
DOI: 10.1080/14740338.2025.2467183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Opinion on Drug Safety, 2025. Verfasst von Lu Yan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Myasthenia Gravis, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Health Research Project of Hunan Provincial Health Commission, the Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University.
Abstract (Originalsprache)
BACKGROUND: Myasthenia gravis (MG) is a rare but serious adverse event (AE) of statins. Yet, its pharmacovigilance and clinical features remain unknown. RESEARCH DESIGN AND METHODS: Data were extracted from the FDA Adverse Event Reporting System (FAERS) (2004 Q1-2023 Q4), and disproportionality analyses were conducted. Case reports on statin-associated MG dated up to 31 December 2023 were retrieved for retrospective analysis. RESULTS: Data from FAERS showed 178,802 AEs of statins, with musculoskeletal disorders being the most common. Compared to other cholesterol-lowering drugs, statins exhibited a significant increase in MG, with 128 reports included, with pravastatin having the highest proportion. Sixteen cases from 12 studies demonstrated atorvastatin was the most frequently reported agent associated with MG. The median age was 58 years, with a male predominance. The main clinical symptoms were ocular muscle weakness, lasting from 1 week to 3 years. Twelve patients were acetylcholine receptor (AChR) antibody positive. All patients discontinued statins, 14 patients received treatment comprising cholinesterase inhibitors and immunosuppressive drugs. Nine patients achieved recovery, and five patients relapsed after steroid reduction or statins re-administration. CONCLUSIONS: In the real-world pharmacovigilance study, statins are associated with increased reporting of MG. Early identification and timely treatment are crucial for the safe use of statins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Hunan Clinical Research Center of Pediatric Cancer, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Förderung
- National Natural Science Foundation of China
- Health Research Project of Hunan Provincial Health Commission
- the Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University
Zitieren
APA
Yan, L., Huang, D., Shen, J., Yang, M., & Wang, S. (2025). Statin‑associated myasthenia gravis: a real-world retrospective and pharmacovigilance study. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2025.2467183
Vancouver
Yan L, Huang D, Shen J, Yang M, Wang S. Statin‑associated myasthenia gravis: a real-world retrospective and pharmacovigilance study. Expert Opinion on Drug Safety. 2025. doi:10.1080/14740338.2025.2467183
BibTeX
@article{Yan2025,
author = {Yan, Lu and Huang, Dan and Shen, Jie and Yang, Minghua and Wang, Shengfeng},
title = {Statin‑associated myasthenia gravis: a real-world retrospective and pharmacovigilance study},
journal = {Expert Opinion on Drug Safety},
year = {2025},
doi = {10.1080/14740338.2025.2467183}
}
EUVIMED